NanoVibronix, Inc. (NAOV)
After hours:
| Previous Close | 0.7680 |
| Open | 0.7750 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.7500 - 0.7999 |
| 52 Week Range | 0.7000 - 4.3400 |
| Volume | |
| Avg. Volume | 60,407 |
| Market Cap | 2.112M |
| Beta (5Y Monthly) | 1.27 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.1200 |
| Earnings Date | May 13, 2024 - May 17, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
NanoVibronix to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024
1x1 Meetings on Thursday, May 2, 2024 ELMSFORD, NY / ACCESSWIRE / April 24, 2024 / NanoVibronix, Inc. (Nasdaq:NAOV) ("NanoVibronix" or the "Company"), a medical device company that produces the UroShieldâ, PainShieldâ and WoundShieldâ Surface Acoustic ...
- Business Wire
NanoVibronix Issues Letter to Stockholders
ELMSFORD, N.Y., April 09, 2024--NanoVibronix, Inc., (NASDAQ: NAOV)("NanoVibronix"), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to stockholders from its Chief Executive Officer, Brian Murphy, providing a review of the fourth quarter and full year 2023 and recent business developments.
- Business Wire
NanoVibronix Signs Agreement for Research and Development of Next Generation PainShield and UroShield
ELMSFORD, N.Y., March 28, 2024--NanoVibronix, Inc. (Nasdaq: NAOV) ("NanoVibronix" or the "Company"), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has entered into an agreement with Veranex, Inc. ("Veranex") to assist with the development of the company’s next generation UroShield and PainShield products.
